

Special Issue

Molecular Research of Cardiocluster

Message from the Guest Editor

Three dimensional cardiac cell- and tissue-engineering models have been proven to be more effective and more relevant for cardiac cell therapy and disease modeling than conventional 2D culturing, thanks to their exquisite multicellular nature and inter-cellular communication that closely resembles in vivo cardiac microenvironment. CardioCluster, cardiac spheres, microtissue, though these 3D organoids come in one common feature they all share is that these 3D cellular structures are engineered with multiple types of progenitor, stromal, or stem cells. Functionally, cardiac organoids are designed to recapitulate the cell diversity of myocardium, protect cell delivery, and promote angiogenesis and cell survival. Additionally, they harbor the advantage as an in vitro surrogate of heart disease model suitable for drug testing and physiological assessment of cardiac tissue.

This Special issue aims to cover the latest developments of 3D cardiac organoids and their therapeutic potentials. Specifically, identification of novel mechanisms on paracrine signaling and inter-cellular communication within the organoids, advantages as cell therapy product, and application as drug testing model.

Guest Editor

Dr. Bingyan J. Wang

Icahn School of Medicine at Mount Sinai, New York, NY, USA

Deadline for manuscript submissions

closed (15 February 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/162283

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).